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Abstract 
Diabetes mellitus is a complex disease resulting in altered glucose homeostasis. In both 
type 1 and type 2 diabetes mellitus, pancreatic β-cells are unable to secrete appropriate 
amounts of insulin to regulate blood glucose level. Moreover in type 2 diabetes mellitus, 
altered insulin secretion is combined with a resistance of insulin-target tissues, mainly 
liver, adipose tissue and skeletal muscle. Both environmental and genetic factors are 
known to contribute to the development of the disease. There is growing evidence that 
microRNAs (miRNAs), a class of small non-coding RNA molecules, are involved in the 
pathogenesis of diabetes. miRNAs function as translational repressors and are emerging 
as important regulators of key biological processes. Here, we review recent studies 
reporting changes in miRNA expression in tissues isolated from different diabetic animal 
models. We also describe the role of several miRNAs in pancreatic β-cells and insulin-
target tissues. Finally, we discuss the possible utilisation of miRNAs as blood biomarkers 
to prevent diabetes development and as tools for gene-based therapy to treat both type 1 
and type 2 diabetes mellitus.  
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Running head: Involvement of microRNAs in diabetes 
 
Abbreviations 
miRNA : microRNA 
IL-1β : Interleukin-1β 
TNF- α : tumor necrosis factor- α 
IFN- γ: Interferon- γ 
3’UTR:  3’untranslated region  
mRNA: messenger RNA 
NOD mice: non obese diabetic mice 
GK rats: Goto-Kakizaki rats  
RNase: ribonuclease 
AAV: adeno-associated vector 
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Introduction 
Diabetes mellitus is the most common metabolic disorder worldwide (1). Due to 
population ageing and increasing trends towards obesity and sedentary lifestyles, the 
number of affected individuals is rising at worrisome rates and is expected to double 
within the next twenty years. In industrialized countries, diabetes is already the leading 
cause of blindness, renal failure and lower limb amputations and is a major risk factor for 
cardiovascular disease and stroke. The pancreatic β-cell and insulin, its secretory product, 
play a central role in the pathophysiology of this disease. Indeed, the release of 
appropriate amounts of insulin in response to circulating levels of glucose and other 
nutrients is essential to achieve blood glucose homeostasis. Thus, insufficient supply of 
this hormone leads to hyperglycemia and progression to overt diabetes. Type 1 diabetes 
mellitus results from the lack of insulin production due to autoimmune destruction of 
pancreatic β-cells. Proinflammatory cytokines produced by infiltrating leucocytes, 
including interleukin-1 β (IL-1β), tumor necrosis factor-α (TNF- α) and interferon-γ 
(IFNγ), play a central role in this process. Type 2 diabetes mellitus (more than 90% of 
cases) is characterized by the release of inappropriate amounts of insulin to maintain 
blood glucose concentration within normal physiological ranges. The pathogenesis of 
type 2 diabetes involves a combination of genetic and environmental/live style factors 
and is frequently associated with obesity (2). Visceral obesity diminishes insulin 
sensitivity of target tissues and the β-cell mass needs to expand to compensate for the 
increase in the metabolic demand. In about one third of obese individuals this adaptive 
process fails, resulting in relative insulin deficiency and development of type 2 diabetes.  
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During the last few years, considerable efforts have been devoted to the elucidation 
of the molecular mechanisms underlying β-cell failure and the development of insulin 
resistance. Global mRNA profiling has provided valuable information concerning 
potential changes in gene expression occurring in β-cells and insulin target tissues in the 
context of diabetes (for review see (3)). It is now becoming clear that microRNAs 
(miRNAs), a new family of regulatory molecules acting downstream or in conjunction 
with transcription factors, make an important contribution to alterations in gene 
expression observed in dysfunctional β-cells and in insulin resistant tissues and are likely 
to be involved in the development of diabetes. 
 
microRNAs as novel regulators of gene expression 
microRNAs are small non-coding RNA molecules of 21-23 nucleotides that regulate 
gene expression (4). They were first discovered in Caenorhabditis elegans in 1993 (5-6) 
and, later on, in vertebrates and plants. Today, thousands of miRNAs have been 
identified, making them one of the most abundant classes of gene regulatory molecules in 
multicellular organisms. These non-coding RNAs behave as specific gene silencers by 
base pairing to 3’untranslated regions (UTR) of target messenger RNAs (mRNAs). 
miRNAs are generally assumed to exert their action by inhibiting translation (4) although 
a recent study, in which the level of miRNAs was artificially modified, suggests that 
these regulatory molecules may control gene expression mainly by affecting mRNA 
stability and degradation (7). 
Most mammalian miRNAs are transcribed by RNA polymerase II as long 
precursor molecules containing stem-loop structures. This primary transcript is cleaved 
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by the Microprocessor complex containing the RNase III-type enzyme Drosha and the 
DGCR8/Pasha protein yielding a ≈ 70 nucleotide hairpin-structured precursor (pre-
miRNA) (8). The pre-miRNA is transported into the cytoplasm and cleaved by another 
RNase III enzyme called Dicer to generate a ≈ 22 nucleotide RNA duplex (9). Upon 
separation of the two strands, the guide strand binds to an Argonaute protein and is 
incorporated into the RISC complex (RNA-induced silencing complex) allowing the 
identification of complementary sites within the 3’ UTRs of target mRNAs (9). Although 
most miRNAs are generated by this canonical pathway, some of these non-coding RNAs 
are produced independently from Dicer (10) and others, called mirtrons, are generated via 
splicing of short hairpin introns (11).  
Based on computational algorithms, around 60% of human transcripts contain 
potential miRNA-binding sites within their 3’ UTRs (12). The most important 
determinant of target recognition is the presence of a “seed sequence” capable of pairing 
to nucleotides 2-8 of the miRNA (13). However, target pairing to the center of some 
miRNAs has also been reported (14). A single miRNA can potentially bind more than 
hundred target mRNAs and multiple miRNAs can cooperate to fine-tune the expression 
of the same transcript (15-17). Although we are only beginning to appreciate the 
extraordinary regulatory potential of these small non-coding RNAs, there are no doubts 
today that they play key roles in a wide variety of physiological processes including cell 
proliferation, apoptosis and tissue differentiation. Moreover, deregulation in miRNA 
biogenesis and function have been shown to contribute to the development of human 
diseases. Thus, it is not surprising that the discovery of an entirely new class of regulators 
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of gene expression prompted several research teams to investigate the potential 
involvement of miRNAs in the development of diabetes and its complications.   
 
Approaches to assess an involvement of microRNAs in diabetes 
To study the potential involvement of miRNAs in diabetes mellitus a wide range of in 
vitro and in vivo strategies can be envisaged. A common and straight forward approach is 
to expose cell lines or isolated primary cells to pathophysiological conditions mimicking 
the diabetic milieu, including elevated concentrations of glucose and/or free fatty acids, 
or cytokines. This permits a detailed analysis of the signaling pathways leading to 
changes in miRNA expression, the study of the functional impact of individual miRNAs 
and the elucidation of the molecular mechanisms underlying their action. Another 
approach is to correlate the alterations in miRNA expression with the development of 
diabetes in animal models or, whenever possible, in diabetic patients. Several diabetes 
animal models either issued from inbreeding or produced by molecular biological 
techniques have specific features (exhaustively described in (18) and (19)), that make 
them appropriate models of type 1 or type 2 diabetes. 
Non-obese (NOD) mice spontaneously develop a form of disease that closely 
resembles type 1 diabetes in humans. Starting around 6 weeks after birth the pancreatic 
islets of NOD mice are progressively surrounded by immune cells. At the age of 13-14 
weeks immune cells penetrate the islets and selectively kill β-cells, resulting in elevation 
of blood glucose levels and development of diabetes. Another widely used model of type 
1 diabetes consists in injecting multiple doses of streptozotocin, a naturally occurring 
compound that is particularly toxic to the insulin-producing β-cells. The most often used 
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models of type 2 diabetes are the ob/ob and db/db mice lacking leptin and leptin receptor, 
respectively, and mice or rats fed for several weeks with a high fat diet (also known as 
diet-induced obesity). These animals become severely obese and insulin resistant, finally 
leading to β-cell failure and hyperglycemia. Goto-Kakizaki (GK) rats, a non-obese 
Wistar substrain which develops insulin resistance and mild hyperglycemia early in life, 
constitutes another popular model of type 2 diabetes mellitus. In the following sections 
we will review the data obtained in these experimental models (see Table1 for a complete 
list of miRNA changes reported in the different diabetic animal models) and highlight the 
characteristics and the functional roles of the miRNAs that were associated with the 
development of diabetes (summarized in Figure 1).  
 
Role of microRNAs in insulin-secreting cells 
miRNAs are necessary for proper pancreatic islet development as demonstrated in a 
mouse model lacking the miRNA processing enzyme Dicer selectively in the pancreas 
(20). Pancreatic specific Dicer-null mice display gross defects in all endocrine pancreatic 
lineages, with insulin-producing β-cells being the most affected. Only a few miRNAs 
have been identified to be preferentially expressed in islets from mice and human and 
their roles in islet development are unknown (21-23), except for miR-375 (24). The 
expression of miR-375, one of the most abundant miRNAs present in islet cells, is under 
the control Pdx-1 and NeuroD1, two critical transcription factors for the development of 
the endocrine pancreas (25). In agreement with these observations, targeted inhibition of 
miR-375 in zebrafish resulted in major defects in pancreatic islet development (24).  
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In mature β-cells miR-375 plays a negative regulatory role in glucose-induced 
insulin secretion (26). Overexpression of miR-375 does not affect ATP production, nor 
the rise in intracellular Ca2+ triggered by glucose, but affects a late step in the insulin 
secretory pathway. This effect was at least partly attributed to a reduction in the 
expression of myotrophin, a protein involved in insulin-granule fusion (26). Later on, 
miR-375 was found to be involved also in the control of insulin gene expression (27). 
The contribution of this miRNA to blood glucose homeostasis has been confirmed in 
miR-375 knockout mice (28). These mice are hyperglycemic and glucose intolerant 
despite normal insulin secretion and clearance. This phenotype results from an increase in 
α-cell number and a consequent elevated plasma glucagon level leading to enhanced 
gluconeogenesis and hepatic glucose output. In contrast, the β-cell mass of these mice is 
decreased as a result of impaired proliferation. Interestingly, genetic deletion of miR-375 
in ob/ob mice profoundly diminished the capacity of the endocrine pancreas to 
compensate for insulin resistance and resulted in a severely diabetic state (28). Therefore, 
miR-375 is important for several features of β-cells, such as insulin expression and 
secretion and β-cell proliferation and adaptation to insulin resistance.   
 
Beside miR-375, other miRNAs participate in the fine tuning of insulin secretion 
by modulating the level of key components of the exocytotic machinery (see Figure 2). 
We observed that a rise in miR-9 relieves an inhibitory control on the expression of 
Granuphilin, a negative regulator of insulin exocytosis, by targeting the transcription 
factor Onecut 2 resulting in defective insulin release in response to stimuli (29). miR-96 
overexpression has a similar impact on Granuphilin expression and insulin secretion, but 
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in this case the effect is independent from Onecut2 (30). Moreover, miR-96 decreases the 
expression of Noc2, a Rab GTPase effector that is necessary for insulin exocytosis. In the 
same study, overexpression of miR-124a was shown to modulate directly or indirectly the 
expression of several components of the exocytotic machinery. This correlated with an 
increase in basal insulin release and a decrease in insulin exocytosis in the presence of 
secretagogues (30). Consistent with these observations, miR-124a was found to induce an 
elevation of intracellular Ca2+ under basal conditions and a reduction in stimulatory 
conditions (31). In the latter study, Foxa2 was identified as a direct target of miR-124a. 
Indeed, downstream Foxa2 target genes, including the ATP-sensitive K+ channel subunits 
Kir6.2 and Sur-1, and the transcription factor Pdx-1 were down-regulated by miR-124a. 
More recently, miR-130a, miR-200 and miR-410 were also described to be involved in 
the regulation of insulin secretion (32).  
The studies cited above used molecular tools to enhance or reduce the expression 
of specific miRNAs in attempt to highlight a potential involvement in the control of 
pancreatic β-cell functions. With the advent of techniques to perform global miRNA 
profiling it became possible to systematically search for miRNAs potentially contributing 
to β-cell dysfunction under physiopathological conditions.  
During the initial phases of type 1 diabetes pancreatic islets are infiltrated by 
immune cells and β-cells become exposed to pro-inflammatory mediators such as IL-1β, 
TNFα and IFNγ. Chronic exposure to these cytokines has a detrimental impact on 
pancreatic β-cell functions leading to a reduction in insulin content, defects in insulin 
secretion and sensitization to apoptosis. Global miRNA profiling of an insulin-secreting 
cell line treated with pro-inflammatory cytokines revealed a strong induction of miR-21, 
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miR-34a and miR-146 (33). Similar effects were observed in freshly isolated human 
pancreatic islets. Moreover, the level of these miRNAs was increased during 
development of pre-diabetic insulitis in pancreatic islets of NOD mice. Interestingly, 
blockade of these miRNAs using antisense molecules prevented the reduction in glucose-
induced insulin secretion provoked by prolonged exposure to IL-1β and protected the β-
cells from cytokine-triggered cell death. The molecular mechanisms involved in the 
protective action of the anti-miRs were partially elucidated. Indeed, anti-miR34 
pretreatment prevented the drop in the expression of the anti-apoptotic protein Bcl2 that 
is normally observed upon prolonged exposure to cytokines. In contrast, blockade of 
miR-146a activity permitted to attenuate c-Jun induction triggered by cytokines, partially 
explaining the amelioration of the survival of β-cells pretreated with anti-miR146. 
Chronic exposure to the free fatty acid palmitate mimics the adverse 
environmental conditions that promote β-cell failure. This results in defective glucose-
induced insulin secretion and sensitization to apoptosis. We found that prolonged 
exposure of insulin-secreting cell lines or pancreatic islets to palmitate leads to an 
increase of miR-34a and miR-146 (34). Moreover, the level of these two miRNAs is 
abnormally elevated in islets isolated from diabetic db/db mice. The rise in miR-34a 
expression resulted from the activation of the p53 pathway and led to sensitization of the 
β-cells to apoptosis and impairment in nutrient-induced insulin secretion (34). These 
effects were associated with a reduction in the expression of the anti-apoptotic protein 
Bcl2 and of VAMP-2, one of the central players in insulin exocytosis. Blockade of miR-
34a or miR-146 activity partially prevented palmitate-induced β-cell apoptosis but was 
insufficient to restore normal secretory activity (34).  
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Hyperglycemia is a hallmark of both type 1 and type 2 diabetes. Prolonged 
exposure of the pancreatic β-cell line MIN6 to high glucose resulted in changes in the 
expression of a large set of miRNAs (35). Among them, miR-124a, miR-107 and miR-
30d were upregulated in hyperglycemic conditions whereas miR-296, miR-484 and miR-
690 were downregulated. Overexpression of miR-30d caused a reduction in insulin gene 
expression, suggesting a possible involvement of this miRNA in defective insulin 
biosynthesis under diabetic conditions. Exposure of insulin-secreting cell lines and 
primary rat islets to elevated glucose concentrations resulted in a reduction in the 
expression miR-375 and a concomitant rise in the level of phosphoinositide-dependent 
protein kinase-1 (PDK1), a direct target of the miRNA that plays a central role in the 
control of insulin gene expression and DNA synthesis (27). Interestingly, the level of 
miR-375 is diminished in the islets of fed diabetic GK rats, suggesting that this glucose-
mediated regulatory mechanism may also operate in vivo (27). 
 
Role of microRNAs in insulin target tissues  
Blood glucose homeostasis requires an appropriate balance between the amount of 
insulin released by β-cells and the sensitivity of the target tissues to the action of the 
hormone. A variety of physiological and pathological events, including obesity, 
pregnancy and stress can diminish insulin sensitivity of peripheral tissues, like liver, 
adipose tissue and skeletal muscle, leading to a condition known as insulin resistance. 
The decreased sensitivity of the tissues to insulin action is normally overcome by an 
increase in insulin secretion. Failure to compensate for insulin resistance leads to chronic 
hyperglycemia and progression to type 2 diabetes. The precise molecular mechanisms 
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underlying insulin resistance is still incompletely understood but a potential involvement 
of miRNAs has been envisaged (see Figure 1 for an overview of miRNAs implicated in 
the regulation of insulin-target tissue functions).  
 
Liver 
Deregulation of miRNA expression in liver may influence glucose homeostasis and 
promote the development of diabetes. Selective deletion of the miRNA processing 
enzyme Dicer in liver early after birth resulted in mild hyperglycemia in the fed state and 
severe hypoglycemia in fasting state due to depletion of glycogen storage (36). 
Hepatocytes from Dicer-null mice displayed an increase in apoptosis, compensatory 
proliferation and elevation of lipid accumulation leading to steatosis. Levels of miR-122, 
miR-148a, miR-192 and miR-194, four miRNAs highly enriched in liver, were down-
regulated in Dicer-null hepatocytes highlighting their possible role in regulating glucose 
and lipid metabolism. 
MiR-122 is the most abundant miRNA in the liver (37) and its role in the control 
of hepatic functions has been studied by different groups (38-40). Intravenous injection 
of antagomir-122, a cholesterol-conjugated antisense oligonucleotide, in mice resulted in 
an almost complete depletion of miR-122 in hepatocytes leading to a decrease in hepatic 
fatty-acid and cholesterol synthesis rates and a concomitant decrease in plasmatic 
cholesterol level. Similar results were obtained in African green monkeys (38). Taken 
together, these results demonstrate an important role for miR-122 in the regulation of 
circulating cholesterol. Moreover, hepatic miR-122 inhibition in a model of diet-induced 
obesity in mouse led to a reduction of plasmatic cholesterol and a significant 
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improvement of liver steatosis, suggesting miR-122 inhibition as a possible therapeutic 
approach to reduce cholesterol levels.  
Global profiling of miRNAs present in liver and adipose tissues revealed a 
marked upregulation of miR-125a in hyperglycemic GK rats compared to 
normoglycaemic Brown-Norway (BN) strains (41). Computational predictions suggest 
that miR-125a can potentially target genes related to glucose and lipid metabolism. Thus, 
upregulation of miR-125a may contribute to deregulation in gene expression leading to 
insulin resistance.  
Several other miRNAs have been reported to be differently expressed in liver of 
diabetic animal models, but their precise role in the regulation of liver function remains 
to be determined (42-44) (see table 1 for a complete list). Among them, miR-335 
expression was upregulated in different obese mice models including ob/ob and db/db 
mice, which correlates with increased liver and body weight and hepatic triglyceride and 
cholesterol levels (45). Further studies will be necessary to understand the regulation of 
miRNAs in the liver during the onset of diabetes and to determine their role on the 
regulation of glucose homeostasis by the liver. 
 
Adipose tissue 
In adipose tissue, insulin stimulates lipogenesis, a process that transforms blood glucose 
into fatty acids to efficiently favor energy storage. Esau et al. were the first to report 
involvement of miRNAs in adipose cell biology (46). They identified miR-143 among 
several miRNAs that were upregulated during human pre-adipocyte differentiation. The 
role of miR-143 in adipocyte differentiation was then confirmed in a second report (47). 
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Both miR-103 and miR-143 were up-regulated during in vitro and in vivo adipogenesis. 
Overexpression of these two miRNAs in pre-adipocytes increased the expression of 
adipogenesis markers and led to triglyceride accumulation. Interestingly, miR-103 and 
miR-143 are downregulated in adipocytes from ob/ob mice, a model of insulin resistance 
and obesity. The mechanism remain to be determined, however, the inflammatory 
pathway is possibly involved (47).  
He et al. discovered that miR-29 family members (miR-29a, b and c) are 
upregulated in the adipose tissue and skeletal muscles of diabetic GK rats (48). Elevation 
of miR-29a and miR-29b could be reproduced in vitro by incubating 3T3-L1 adipocytes 
in the presence of high glucose and insulin. These conditions are known to induce insulin 
resistance, pointing to a possible role for miR-29 in this process in adipocytes. Indeed, 
overexpression of miR-29 in 3T3-L1 adipocytes decreased insulin-stimulated glucose 
uptake presumably by inhibiting insulin signaling through AKT phosphorylation. Taken 
together, these results suggest that miR-29 could mediate part of mechanisms leading to 
insulin resistance in type 2 diabetes.   In a similar study, Herrera et al investigated miRNA 
profiling in insulin target tissues from hyperglycemic GK rats, intermediate glycemic 
Wistar Kyoto rats and normoglycemic Brown-Norway rats (43). Among the 29 miRNAs 
differently expressed between the three rat strains, five of them correlated with the 
glycemic phenotype of the strain: miR-195 and miR-103 in liver, miR-222 and miR-27a 
in adipose tissue, and miR-10b in muscle. These results suggest a role for those 5 
miRNAs in the pathogenesis of type 2 diabetes, but their function in the regulation of 
insulin-target tissues remains to be elucidated. 
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Skeletal muscle 
Skeletal muscle is a major site of glucose disposal, where insulin favors glucose storage 
in glycogen form. So far only few studies analyzed changes in miRNA expression in 
human tissues in the context of diabetes. Granjon et al. investigated the impact of insulin 
on skeletal muscle’s miRNA expression by analyzing muscle biopsies taken from healthy 
subjects before and after 3 hours of euglycemic-hyperinsulinemic clamp (49). Insulin 
down-regulated 39 miRNAs, including miR-1, miR-206 and miR-133a well known for 
their role in muscle development and growth and miR-29a and miR-29c highly enriched 
in insulin sensitive-tissues (50). Downregulation of miR-1 and miR-133a by insulin was 
found to be mediated by the transcription factors SREBP-1c and MEF2C. The effect of 
insulin on these two miRNAs was altered in skeletal muscle of type 2 diabetic patients, 
which corroborates the impairment of MEF2C and SREBP-1c stimulation in the same 
conditions (49, 51). In non insulin-stimulated condition, Granjon et al. did not observe 
significant differences in miR-1 and miR-133a expression in skeletal muscle of diabetic 
versus healthy subjects. The results from this study are controversial since other 
laboratories could not reproduce some of the key findings. Indeed, Nielsen et al. using a 
larger number of subjects did not detect any changes in miR-1, miR-133a and miR-206 
expression in response to a 3 hours euglycemic-hyperinsulinaemic clamp (52), despite 
measuring a decrease in the level of these miRNAs upon endurance training. A decrease 
in the expression of several miRNAs upon endurance training improving insulin 
sensitivity, including miR-1 and miR-133a, was confirmed in an additional study (53). 
More recently, Gallagher et al. detected alterations in about 60 miRNAs in lean, drug 
free, type 2 diabetic subjects (54). Interestingly, many of these changes appeared to occur 
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prior to the onset of diabetes. In the latter study, miR-133a expression was reduced by 
five-fold in type 2 diabetic patients and altered levels of this miRNA correlated with 
higher fasting glucose levels and other important clinical parameters including HOMA1 
and HbA1c. Gene Ontology profiles of the highest ranked targets of the miRNAs affected 
in type 2 diabetic patients highlighted a significant enrichment in genes involved in 
metabolic and developmental processes. 
 
 Similar studies were carried out in GK rats, a model of insulin resistance and 
diabetes. miRNA profiling in skeletal muscle of GK rats was compared to non-diabetic 
control rats (43, 48, 55). A total of 25 changes were reported by these 3 studies (see Table 
1), but only miR-130a upregulation was commonly found in two on them. Also, only 
miR-29 family was investigated for its role in the insulin resistance, as discuss above 
(48). Finally, neither miR-1 nor miR-133a expression was reported to be altered in GK 
rats. More complete studies are now necessary to determine the mechanisms linking 
hyperglycemia, miRNA deregulation and insulin resistance in the context of diabetes. 
 
The role of miR-1 and miR-133a in the regulation of glucose homeostasis was 
also investigated in vitro. MiR-133a/b has been shown to decrease GLUT4 expression, 
leading to a reduction of insulin-induced glucose uptake in cardiomyocytes (56). This 
effect was proposed to be mediated by inhibiting the expression of the Krüppel-like 
transcription factor KLF15, a direct target of miR-133a/b. Human ether-a-go-go (HERG) 
and KCNQ1 are two other identified targets of miR-133a/b. Both are involved in the 
formation of potassium (K+) current channel in heart and could be involved in the long 
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QT syndrome in diabetic patients (57-58). miR-1 regulation and function were also first 
investigated in cardiomyocytes, but results were confirmed in C2C12 myotubes. 
Exposure of cardiomyocytes to high glucose induces apoptosis with a concomitant 
elevation of miR-1 expression (59). Two identified targets of miR-1, IGF-1 and IGF-1 
receptor (59-60), were involved in this process since glucose-induced mitochondria 
dysfunction, cytochrome c release and apoptosis were prevented by IGF-1 
overexpression. A feedback loop between miR-1 and IGF-1 was observed in both C2C12 
myotubes and cardiomyocytes, in which IGF-1 regulated miR-1 expression via the 
transcription factor Foxo3a (60).  
 
microRNAs as potential biomarkers for diabetes 
Recent studies reported detection of miRNAs in blood and other body fluids (61-
64). Levels of miRNAs in serum samples from humans and other animals were found to 
be stable, reproducible, and consistent among individuals (61-62). To verify if plasma 
miRNAs were coming only from blood cell disruption, plasma miRNAs were compared 
to blood-cell miRNAs. A majority of miRNAs were found to be common, but several 
were only found in serum (61). These results suggest that at least part of the circulating 
miRNAs originate from cells located outside of blood vessels.  
The presence of miRNAs in the blood may at first seem surprising since serum 
contains ribonucleases (RNase). However, plasma miRNAs are resistant to RNase 
digestion and to several harsh laboratory conditions (61-62). As evidenced by many 
reports, miRNAs are not present in the blood in native form but are released in 
microvesicular structures, such as exosomes or apoptotic bodies, and circulate inside 
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these membrane-delimited vesicles that protect them from degradation. Circulating 
microvesicles are thought to favour cell-to-cell communication, but also to exchange 
genetic information between healthy and injured cells and tissues (65-66). In fact, 
specific tumor miRNAs were identified in serum from cancer patients (67). Therefore, 
miRNA profiling from microvesicles circulating in the blood could reflect the physio-
pathological state of an individual.  
Chen et al. (61) compared serum miRNA profiles from diabetic and healthy 
subjects and identified 65 commonly and 42 differently expressed miRNAs. Since no 
detail was given on miRNA identity and on the clinical parameters of diabetic patients, it 
is hard to draw conclusions from these observations. However, these results suggest that 
plasma miRNAs could vary according to healthy or disease state, making them attractive 
new biomarkers. In the context of diabetes, biomarkers could be particularly useful to 
prevent the development of the disease since diabetic patients are generally detected too 
late. The recent study of Zampetaki et al. (68) highlighted the promising utilisation of 
plasma miRNAs as biomarkers. The authors determined miRNAs levels in plasma 
samples obtained from a large prospective population-based study including more than 
800 individuals. Among them, 80 subjects were type 2 diabetic patients and 19 
individuals that were normoglycemic at the beginning of the study developed type 2 
diabetes during the 10 years survey. The comparison of pooled plasma miRNAs from 
diabetic subjects with age- and sex-matched controls led to the identification of 13 
miRNAs differently expressed in diabetic patients. Among them, the expression of 5 
miRNAs, miR-15a, miR-28-3p, miR-126, miR-223, and miR-320, was already altered 
before the manifestation of the disease. The determination of the level of this cluster of 5 
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miRNAs was sufficient to identify 70% of the type 2 diabetic patients. The diabetic 
subjects escaping detection had lower fasting glucose levels or were patients will well-
controlled diabetes. Interestingly, 52% of the normoglycemic individuals that developed 
diabetes during the following 10 years were already classified in the diabetic group. 
Taken together, these results suggest for the first time the existence of a unique miRNA 
blood signature that could help with other factors distinguishing between individuals with 
prevalent or incident diabetes from healthy controls.  
The validity of this miRNA signature as a tool to diagnose type 2 diabetes 
remains to be confirmed by other large independent studies. Also, similar investigations 
should be carried out to determine whether the same or other miRNA signatures can 
efficiently recognize individuals at risk to develop type 1 diabetes. This would 
complement the information obtained by the measurement of other biomarkers favouring 
the identification of subjects that would benefit for treatments aiming at preventing auto-
immune degradation of pancreatic β-cells. Nonetheless, blood level of miRNAs is a 
promising strategy to prevent diabetes development. 
 
MicroRNAs: promising targets for gene-therapy based treatment? 
As outlined above, deregulation of miRNA functions has been linked to several human 
disorders, including diabetes. Whether the disease is a direct cause of altered miRNA 
expression or this altered expression occurs as a consequence of the pathological state is 
still unknown. Nonetheless, restoration of miRNA functions to normal levels is an 
attractive therapeutic strategy.  
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Different chemically modified oligonucleotides have been used in vitro to 
modulate miRNA expression (for a complete review, see (69)). Among them, miRNA-
mimic oligonucleotides increase the expression of a miRNA of interest. Locked nucleic 
acid (LNA)-antimiRs, antagomirs, and morpholinos are efficient inhibitors of miRNA 
functions and are effective also in vivo (38, 40, 70). The use of oligonucleotides for gene 
therapy has to face different obstacles because these molecules are relatively unstable and 
their effects are transient. Therefore, they have to be injected at high doses and 
necessitate repeated deliveries. Moreover, methods permitting cell-specific delivery of 
these molecules are not yet available.  
The generation of vectors in which miRNA-mimics are placed under the control 
of an inducible promoter permits to achieve a temporally controlled elevation of miRNA 
expression in vivo (71). Moreover, the use of specific promoters permit the targeting of 
the miRNA in a particular cell-type. In this context, adeno-associated virus (AAV) 
vectors have shown promising results for gene therapy. Different capsid serotypes have 
been tested to improve AAV-gene transduction in specific target tissues. AAV packaged 
in capsid serotypes 6, 8 and 9 are largely directed to skeletal muscle, liver and heart, 
respectively, following systemic delivery in small animal models (72). The use of insulin 
promoter to control gene expression in an AAV8 vector enabled specific delivery of IL-4 
to pancreatic β-cells permitting to prevent their destruction and delaying the appearance 
of diabetes in NOD mice (73). Following promising preclinical studies in small animals, 
50 human clinical trials using AAV-mediated gene transfer have been approved (72).  
So far AAV vectors have been used mostly for the delivery of protein-coding 
genes but Kota et al. (74) took advantage of this system to overexpress a miRNA. In their 
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study, miR-26a, which is highly expressed in diverse healthy tissues but decreased in 
liver cancer cells, was packaged in AAV8 serotypes and injected only once in mouse tail-
vein. Animals injected with AAV8.miR26a showed an important protection from hepatic 
cancer progression with no sign of toxicity. Taken together, these results suggest that 
AAV-miRNA strategy is a very promising therapeutic approach for miRNAs highly 
expressed, and therefore tolerated, in normal tissues and underexpressed in the disease 
state.  
Alternative strategies to chemically modified oligonucleotides have also been 
designed to reduce miRNA functions in vivo. Currently, the most promising approach 
involves the use of “miRNA sponges”. MiRNA sponges are artificial miRNA decoys that 
bind and hold native miRNA, in order to compete with natural targets and then create a 
loss-of-function of the miRNA of interest. MiRNA sponges contain multiple binding sites 
directed against one particular miRNA or a miRNA seed family. They are particularly 
efficient in vitro (75). Recent studies have used this strategy in vivo to stably decrease the 
activity of miR-31 or of the miR-15a/16-1 cluster and to investigate their role in cancer 
development (76-77). Since those two studies used miRNA sponges to favour cancer 
development, the use of miRNA sponges as a therapeutic treatment still has to be 
investigated. Their long-term effects and tissue-specific delivery will also have to be 
determined. Nonetheless, the expression of miRNA sponges in an AAV vector delivery 
system is an attractive strategy for preclinical gene-therapy studies. 
 
Conclusions 
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MiRNAs are emerging as key regulators of gene expression. Type 1 and type 2 diabetes 
are associated with alterations in the level of several miRNAs in insulin-secreting cells as 
well as in insulin-target tissues. We already have at our disposal molecules capable of 
efficiently modulating the expression of miRNAs in vitro and in vivo. Unfortunately, at 
present approaches to selectively target these molecules in a cell-specific manner are 
missing. The development of techniques allowing in vivo delivery of miRNA mimics or 
anti-miRs specifically in β-cells and insulin-target tissues could permit to correct the 
level of key miRNAs under diabetic conditions and open the way to new strategies for 
treating the disease. However, safety concerns and cost effectiveness will need to be 
carefully evaluated to determine whether approaches aiming at restoring miRNA levels 
are appropriate for the treatment of a chronic disease such as diabetes. In addition to 
alteration in insulin-producing cells and insulin target tissues, diabetes is also associated 
with distinct changes in the blood miRNA profile. In the future, measurements of the 
level of specific miRNAs may become useful tools to identify individuals at risk for 
developing type 1 or type 2 diabetes, hopefully preventing the development of the 
disease.  
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 Table legend 
Table 1 : List of miRNAs reported to be differently expressed in pancreatic β-cells, liver, 
adipose tissue and/or skeletal muscle of animal models of type 1 or type 2 diabetes. a) 
See text for more details on animal models. b) miRNAs in bold are upregulated in the 
diabetic state whereas miRNAs in italic are downregulated. 
 
 
Figure legends 
Figure 1: Schematic overview of the miRNAs involved in the regulation of the functions 
of pancreatic β-cells or insulin-target tissue in the context of diabetes. 
 
Figure 2 : Regulation of insulin exocytosis by miRNAs. The figure depicts the miRNAs 
that control directly or indirectly the expression of key components required for β-cell 
exocytosis associated either with insulin containing secretory granules or with the plasma 
membrane. 
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Animal modelsa Characteristics Tissue Detection miR changesb References
TYPE 1 DIABETES ANIMAL MODELS
Non obese diabetic (NOD) - susceptibility to spontaneous pancreatic islets qPCR miR-21,-34a, -146a Roggli E, 2010
mice development of T1D
streptozotocin-induced - destruction of B-cell by repeated liver array miR-34a Li S, 2009
T1D mice injection of streptozotocin miR-122
TYPE 2 DIABETES ANIMAL MODELS
db/db mice - leptin receptor gene deficiency pancreatic islets qPCR miR-34a,-146a Lovis P, 2008
- obese, hyperglycemic, liver array miR-19a, -183, -207, -212, -326, -328, -335, -409, 434-3P, 467 Nakanishi N, 2009
  hyperinsulinemic miR-33, -34c, -129-3P, -133a, -137, -142-5P, -144, -146, -384, -448
- insulin resistant adipose tissue qPCR miR-335 Nakanishi N, 2009
ob/ob mice - leptin gene deficiency liver array miR-31, -34a, -103, -107, -194, 200a, -221, -335-5P Li S, 2009
- obese, hyperglycemic, miR-2, -29c, -122, -451
  hyperinsulinemic qPCR miR-335 Nakanishi N, 2009
- insulin resistant adipose tissue array miR-146b, -221, -222 Xie H, 2009
miR-30a-5P, -30c, -99b, -103, -107, -125b, -143, -148a, -422b
qPCR miR-335 Nakanishi N, 2009
BTBR-ob & B6-ob mice vs - diabetes-susceptible BTBR mice pancreatic islets array miR-34a, -34b, 132, -133a, -126-5P, -152, -185, -212 Zhao E, 2009
BTBR & B6 mice   or diabetes-resistant B6 mice miR-7b, -31, -184, -204
  were inbreed with ob/ob mice liver array miR-34a, -205 Zhao E, 2009
- obese miR-17-3P, -133a, -151, -201, -298, -328, -329, -330, -380-5p
- mild and transient (B6-ob) or adipose tissue array miR-221, -222, -342 Zhao E, 2009
  severly (BTBR-ob) hyperglycemic miR-1, -34b, -34c, -133b, -135a, -141, -200a, -200b, -200c, -215, -375, -429
Goto-Kakizaki (GK) rats - non-obese Wistar substrain  pancreatic islets qPCR miR-124a El Ouaamari, 2008
- develop T2D early in life miR-375
liver Northern miR-29a,-29b,-29c He A, 2007
array miR-125a Herrera BM, 2009
array miR-103, -195 Herrera BM, 2010
adipose tissue Northern miR-29a,-29b,-29c He A, 2007
array miR-125a Herrera BM, 2009
array miR-222, -27a Herrera BM, 2010
muscle array miR-29a,-29b,-29c,-150 He A, 2007
miR-19b, -127, -130a, -148a, -152,  -199a, -299-5P, -335, -379, -343-3P, -451
array let-7f, miR-301 Huang B, 2009
miR-23a, -23b, -24,-126,-130a, -424, -450
array miR-10b Herrera BM, 2010
